

# Chengheng Liao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6737252/publications.pdf>

Version: 2024-02-01

19  
papers

672  
citations

623734

14  
h-index

888059

17  
g-index

23  
all docs

23  
docs citations

23  
times ranked

735  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P5-05-01: Metabolite profiling and RNA-seq identifies novel metabolomic-genomic biomarker and therapeutic options for rapidly proliferating breast cancers. <i>Cancer Research</i> , 2022, 82, P5-05-01-P5-05-01.	0.9	0
2	Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. <i>Cancer Research</i> , 2022, 82, 665-680.	0.9	5
3	An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. <i>Molecular Cell</i> , 2022, 82, 3030-3044.e8.	9.7	18
4	Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications. <i>Cells</i> , 2021, 10, 678.	4.1	53
5	mRNA Delivery of a Bispecific Single-Domain Antibody to Polarize Tumor-Associated Macrophages and Synergize Immunotherapy against Liver Malignancies. <i>Advanced Materials</i> , 2021, 33, e2007603.	21.0	61
6	ZHX2 promotes HIF1 $\alpha$ oncogenic signaling in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	6.0	21
7	TBK1 Is a Synthetic Lethal Target in Cancer with <i>VHL</i> Loss. <i>Cancer Discovery</i> , 2020, 10, 460-475.	9.4	63
8	Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1706-1721.	9.4	35
9	BBOX1 promotes triple-negative breast cancer progression by controlling IP3R3 stability. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1813526.	0.7	3
10	USP37 promotes deubiquitination of HIF2 $\alpha$ in kidney cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13023-13032.	7.1	24
11	Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases. <i>American Journal of Pathology</i> , 2020, 190, 1584-1595.	3.8	33
12	Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987619.	3.2	0
13	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	12.6	134
14	GlnR and PhoP Directly Regulate the Transcription of Genes Encoding Starch-Degrading, Amyolytic Enzymes in <i>Saccharopolyspora erythraea</i> . <i>Applied and Environmental Microbiology</i> , 2016, 82, 6819-6830.	3.1	22
15	Nitrogen regulator GlnR controls uptake and utilization of non-phosphotransferase-system carbon sources in actinomycetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15630-15635.	7.1	80
16	DasR is a pleiotropic regulator required for antibiotic production, pigment biosynthesis, and morphological development in <i>Saccharopolyspora erythraea</i> . <i>Applied Microbiology and Biotechnology</i> , 2015, 99, 10215-10224.	3.6	19
17	Three genes encoding citrate synthases in <i>Saccharopolyspora erythraea</i> are regulated by the global nutrient-sensing regulators GlnR, DasR, and CRP. <i>Molecular Microbiology</i> , 2014, 94, 1065-1084.	2.5	34
18	Control of chitin and N-acetylglucosamine utilization in <i>Saccharopolyspora erythraea</i> . <i>Microbiology (United Kingdom)</i> , 2014, 160, 1914-1928.	1.8	20

#	ARTICLE	IF	CITATIONS
19	GlnR-mediated regulation of nitrogen metabolism in the actinomycete <i>Saccharopolyspora erythraea</i> . <i>Applied Microbiology and Biotechnology</i> , 2014, 98, 7935-7948.	3.6	47